Skip to content

To explore the mechanism on the treatment of oligoasthenospermia by kidney-tonifying and spermatogenic method based on differential expression of miRNAs: Study protocol for a prospective single arm study

To explore the mechanism on the treatment of oligoasthenospermia by kidney-tonifying and spermatogenic method based on differential expression of miRNAs

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070612
Enrollment
Unknown
Registered
2023-04-18
Start date
2023-05-01
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oligoasthenospermia

Interventions

Treatment group:Wuzi Yanzong pill

Sponsors

The First Affiliated Hospital of Henan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the diagnostic criteria for ligoasthenospermia and kidney essence deficiency syndrome; (2) 20~50 years old; (3) Those who have cohabited together for more than 1 year after marriage, the couple's sexual life is normal, the woman has no fertility disease and failed to conceive due to the man's semen; (4) Those who have not used other Chinese or Western medicines to improve semen quality in the 1 month prior to being included in the observation; (5) Those who have been approved by the hospital's ethics committee and have voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Those whose age does not meet the inclusion criteria; (2) Those suffering from inflammatory diseases of the genitourinary system; (3) Abnormal level of endocrine sex hormone detection; (4) Abnormal sex chromosome karyotype detection; (5) Patients with severe varicocele or hydrocele testicular; (6) Patients with cryptorchidism or other testicular dysplasia; (7) Abnormal AZF genetic testing; (8) Severe liver and kidney function damage; (9) Those who are taking hormonal drugs, antitumor drugs, immunosuppressants and other drugs that are not conducive to treatment.

Design outcomes

Primary

MeasureTime frame
Expression of differential miRNAs ;

Countries

China

Contacts

Public ContactBaojun Ju

The First Affiliated Hospital of Henan University of Chinese Medicine

7743857@qq.com+86 18638141073

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026